Challenges of CAR- and TCR-T cell–based therapy for chronic infections

Authors: Antonio Bertoletti, Anthony Tanoto Tan

Published: 2020-03-12

DOI: 10.1084/jem.20191663

Source: Full article

---

Abstract

While therapy with T cells engineered with a chimeric antigen receptor (CAR) or a classical T cell receptor (TCR) is revolutionizing cancer treatment, its adoption in infectious diseases has been met with considerable resistance. Can we find its value for the cure of infections?